Project Grant K99HL183966
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $111K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Shreveport, LA 71130, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Louisiana State University Health Sciences Center-Shreveport $737,242 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate macrophage one-carbon metabolism in atherosclerotic plaque stability. The recipient will conduct research examining serine hydroxymethyltransferase 2 (SHMT2)-dependent one-carbon metabolism in macrophages and its role in maintaining plaque stability and preventing atherosclerotic...
- The National Heart, Lung, and Blood Institute awarded Louisiana State University Health Sciences Center-Shreveport $737,455 on May 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate provisional matrix-binding integrins as therapeutic targets in advanced atherosclerosis. The research examines how wound-associated extracellular matrix proteins promote atherogenic inflammation and plaque vulnerability, and tests whether combined deletion of α5 and αV integrins...
- The National Heart, Lung, and Blood Institute awarded Louisiana State University Health Sciences Center-Shreveport $732,705 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how cellular reductive state regulates inflammation resolution in atherosclerotic disease. The recipient will determine the influence of changing glutathione ratios (GSH:GSSG) on protein glutathionylation driving MERTK signaling in efferocytosis, the process by which...
- The National Heart, Lung, and Blood Institute awarded Louisiana State University Health Sciences Center-Shreveport $842,500 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of cell-specific programmed death-ligand-1 (PD-L1) in cardiac pathophysiology following ischemic injury and in immune checkpoint inhibitor-mediated cardiotoxicity. The research examines how PD-L1 expression in fibroblasts and myeloid cells regulates repair and...
- The National Heart, Lung, and Blood Institute awarded Louisiana State University Health Sciences Center-Shreveport $248,679 on February 18, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the nuclear protein HMGXB4 in occlusive vascular diseases. The research examines vascular smooth muscle cell phenotypic modulation in restenosis and atherosclerosis. The project focuses on elucidating how HMGXB4 regulates the transition from contractile to...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $618,352 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the mechanical regulation of endothelial lipid droplet metabolism and its role in vascular dysfunction. The research examines how oscillatory shear stress suppresses triglyceride hydrolysis by inactivating the transcription factor FOXO1, leading to lipid droplet accumulation in...
- The National Heart, Lung, and Blood Institute awarded New York University $836,736 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial mechanosensing of circulatory flow in health and disease. The project will examine how endothelial cells lining blood and lymphatic vessels respond to fluid flow forces, with focus on the roles of PLXND1 (a transmembrane semaphorin receptor) and KLF2 (a transcription factor) in endothelial responses to...
- The National Institutes of Health National Heart, Lung and Blood Institute awarded Boston Children's Hospital $1,628,604 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct molecular research on atherosclerosis regulation, with performance through June 30, 2028. The project investigates endothelial dysfunction and chronic inflammation as critical regulators of plaque destabilization in atherosclerosis, focusing on the role of CD47 as a cell-surface...
- The National Heart, Lung, and Blood Institute awarded New York University $763,960 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the molecular mechanisms by which long non-coding RNA IRF1-AS1 and its mouse ortholog GM12216 regulate atherosclerotic cardiovascular disease. The research will examine how IRF1-AS1 coordinates expression of protein-coding genes including the transcriptional regulator IRF1 in myeloid cells to drive atherogenesis,...
- The National Heart, Lung, and Blood Institute awarded East Tennessee State University $536,447 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2026, to investigate mechanisms of macrophage retention in the extracellular matrix during atherosclerosis development. The project examines how oxidation of polyunsaturated fatty acids—including docosahexaenoic acid, arachidonic acid, and linolenic acid—generates adhesive substrates in vascular tissue that anchor...